New drug trial targets rare blood disorder in untreated patients
NCT ID NCT07387302
Summary
This study is testing an investigational drug called SLN12140 for adults with paroxysmal nocturnal hemoglobinuria (PNH) who have never taken a complement inhibitor medication. The main goal is to see if SLN12140 can safely reduce the destruction of red blood cells, which is the core problem in PNH. Researchers will measure this by tracking blood markers and symptoms over a 12-week treatment period.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.